Ken Griffin Akebia Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 91,800 shares of AKBA stock, worth $182,682. This represents 0.0% of its overall portfolio holdings.

Number of Shares

91,800

Previous 135,100 32.05%

Holding current value

$182,682

Previous $247,000 62.35%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.86 - $1.63 $113,034 - $214,239	131,435 Added 157.91%	214,669 $218,000
Q1 2024 May 15, 2024	SELL	$1.27 - $2.24 $133,807 - $236,006	-105,360 Reduced 55.87%	83,234 $152,000
Q4 2023 Feb 14, 2024	BUY	$0.8 - $1.28 $150,875 - $241,400	188,594 New	188,594 $233,000
Q2 2023 Aug 14, 2023	BUY	$0.51 - $1.43 $492 - $1,379	965 New	965 $0
Q4 2022 Feb 14, 2023	SELL	$0.25 - $0.58 $71,944 - $166,910	-287,777 Reduced 95.55%	13,397 $7,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $46,838 - $71,819	-156,129 Reduced 34.14%	301,174 $95,000
Q2 2022 Aug 15, 2022	BUY	$0.32 - $0.67 $737 - $1,545	2,306 Added 0.51%	457,303 $162,000
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $79,848 - $324,937	-110,900 Reduced 19.6%	454,997 $326,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $963,661 - $1.42 Million	426,399 Added 305.67%	565,897 $1.28 Million
Q3 2021 Nov 15, 2021	SELL	$2.35 - $3.88 $153,271 - $253,061	-65,222 Reduced 31.86%	139,498 $402,000
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $473,727 - $703,059	-167,395 Reduced 44.98%	204,720 $775,000
Q1 2021 May 17, 2021	SELL	$2.92 - $5.06 $1.78 Million - $3.08 Million	-608,146 Reduced 62.04%	372,115 $1.26 Million
Q4 2020 Feb 16, 2021	BUY	$2.22 - $3.78 $1.25 Million - $2.13 Million	563,132 Added 135.0%	980,261 $2.75 Million
Q3 2020 Nov 16, 2020	BUY	$2.39 - $13.08 $880,444 - $4.82 Million	368,387 Added 755.79%	417,129 $1.05 Million
Q2 2020 Aug 14, 2020	SELL	$6.67 - $13.58 $1.14 Million - $2.32 Million	-170,539 Reduced 77.77%	48,742 $662,000
Q1 2020 May 15, 2020	SELL	$4.1 - $10.24 $2.82 Million - $7.05 Million	-688,939 Reduced 75.86%	219,281 $1.66 Million
Q4 2019 Feb 14, 2020	BUY	$3.16 - $6.73 $1.7 Million - $3.62 Million	537,470 Added 144.97%	908,220 $5.74 Million
Q3 2019 Nov 14, 2019	BUY	$3.55 - $5.4 $952,173 - $1.45 Million	268,218 Added 261.59%	370,750 $1.45 Million
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $287,352 - $564,192	70,086 Added 216.01%	102,532 $497,000
Q1 2019 May 15, 2019	SELL	$5.41 - $8.73 $7.61 Million - $12.3 Million	-1,407,296 Reduced 97.75%	32,446 $0
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $2.41 Million - $4.1 Million	447,966 Added 45.17%	1,439,742 $7.96 Million
Q3 2018 Nov 13, 2018	BUY	$7.44 - $10.65 $2.76 Million - $3.96 Million	371,440 Added 59.88%	991,776 $0
Q2 2018 Aug 10, 2018	BUY	$9.15 - $11.34 $3.58 Million - $4.43 Million	391,022 Added 170.52%	620,336 $0
Q1 2018 May 11, 2018	BUY	$9.53 - $15.68 $2.19 Million - $3.6 Million	229,314 New	229,314 $2.19 Million

Others Institutions Holding AKBA

# of Institutions

115

Shares Held

53.6M

Call Options Held

540K

Put Options Held

236K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $366M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account